Table 2 Clinicopathologic characteristics of studied subjects. Comparison of clinical and pathological features of NRAS mutated primary melanomas according to the NRAS mutant allelic burden (<60% or ≥60%)
From: Variation of mutant allele frequency in NRAS Q61 mutated melanomas
≥60% οf Μ% ΝRΑS n = 24/72 (33.3%) | <60% οf Μ% ΝRΑS n = 48/72 (66.7%) | P-value (statistic test) | |
|---|---|---|---|
Origin of pyrosequencing sample | |||
From primary melanoma | 5 | 8 | 0.91 (Chi2with Yates’ correction) |
From metastasis | 19 | 40 | |
Age | |||
Mean, years (SD) | 63.1 ± 17.4 | 65.2 ± 14.7 | 0.61 (Student) |
Median, year [range] | 60 [37–93] | 66 [32–97] | |
Gender | |||
Ratio M/F | 13/11 | 30/18 | 0.49 (Chi2) |
Breslow index | |||
Mean, mm (SD) | 3.0 ± 2.1 | 3.3 ± 2.2 | 0.57 (Student) |
Median, mm [range] | 3.00 [0.40–10.00] | 2.61 [0.50–9.00] | |
Ulceration | 14 | 20 | 0.14 (Chi2) |
Mitotic activity | 11 | 31 | 0.45 (Chi2) |
Initial AJCC stage | |||
I | 5 | 10 | 0.7 (Chi2) |
IA | 4 | 2 | |
IB | 1 | 8 | |
II | 11 | 26 | |
IIA | 4 | 10 | |
IIB | 6 | 5 | |
IIC | 1 | 11 | |
III | 7 | 9 | |
IIIA | 0 | 2 | |
IIIB | 4 | 2 | |
IIIC | 3 | 6 | |
IV | 1 | 0 | |
NA | 0 | 2 | |
Histologic subtype | |||
Nodular melanoma | 9 | 19 | 0.63 (Chi2) |
SSM | 10 | 22 | |
Acral melanoma | 1 | 0 | |
Lentigo maligna melanoma | 0 | 1 | |
Mucosal melanoma | 0 | 1 | |
On congenital naevus | 0 | 1 | |
Inclassable | 1 | 2 | |
NA | 3 | 2 | |